Table 2.
Baseline demographic and clinical characteristics.
| Adjuvant chemotherapy | Adjuvant chemoradiotherapy | Observation | |
|---|---|---|---|
| No. | 124 | 53 | 77 |
| Age (median) | 56 | 50 | 62 |
| Sex—no. (%) | |||
| Male | 81 (65.32) | 32 (60.38) | 56 (72.73) |
| Female | 43 (34.68) | 21 (39.62) | 21 (27.27) |
| ECOG performance status—no. (%) | |||
| 0 | 63 (50.81) | 28 (52.83) | 28 (36.36) |
| 1 | 58 (46.77) | 24 (45.28) | 43 (55.84) |
| ≥2 | 0 (0) | 0 (0) | 4 (5.20) |
| Missing data | 3 (2.42) | 1 (1.89) | 2 (2.60) |
| AJCC stage (TNM classification)—no. (%) | |||
| IB | 10 (8.06) | 2 (3.77) | 4 (5.19) |
| IIA | 26 (20.97) | 6 (11.32) | 8 (10.39) |
| IIB | 20 (16.13) | 7 (13.21) | 18 (23.38) |
| IIIA | 23 (18.55) | 15 (28.30) | 17 (22.08) |
| IIIB | 39 (31.45) | 20 (37.74) | 25 (32.47) |
| IIIC | 6 (4.84) | 3 (5.66) | 5 (6.49) |
| Primary tumor classification stage—no. (%) | |||
| T1 | 6 (4.83) | 4 (7.55) | 0 (0) |
| T2 | 21 (16.94) | 9 (16.98) | 14 (18.18) |
| T3 | 86 (69.35) | 36 (67.92) | 55 (71.43) |
| T4 | 11 (8.88) | 4 (7.55) | 8 (10.39) |
| Regional lymph nodes classification—no. (%) | |||
| N0 | 23 (18.55) | 2 (3.77) | 12 (15.59) |
| N1 | 32 (25.81) | 6 (11.32) | 14 (18.18) |
| N2 | 23 (18.55) | 19 (35.85) | 16 (20.78) |
| N3 | 46 (37.09) | 26 (49.06) | 35 (45.45) |
| Lauren classification—no. (%) | |||
| Intestinal | 41 (33.06) | 8 (15.09) | 26 (33.77) |
| Diffuse | 64 (51.61) | 40 (75.47) | 37 (48.05) |
| Mixed | 19 (15.33) | 5 (9.44) | 14 (18.18) |
| Adjuvant chemotherapy—no. (%) | |||
| S-1 | 20 (16.13) | 2 (3.77) | – |
| Capecitabine | 12 (9.68) | 2 (3.77) | – |
| XELOX | 9 (7.26) | 1 (1.89) | – |
| SOX | 37 (29.84) | 29 (54.71) | - |
| FOLFOX | 36 (29.03) | 17 (33.08) | - |
| Paclitaxel-based agents | 10 (8.06) | 1 (1.89) | - |
| 3-year disease-free survival rate (95% CI) | 66.06 (56.87–73.75) | 66.04 (51.64–77.06) | 44.71 (33.34–55.43) |
| Number of disease recurrence events—no. (%) | 62 (50.00) | 21 (39.62) | 53 (68.83) |
| Number of patients received salvage treatments—no. (%) | 35 (56.45) | 16 (76.19) | 24 (45.28) |
Data are expressed as number (%) or rate (95% CI) as appropriate.
XELOX, Capecitabine + Oxaliplatin; SOX, S-1 + Oxaliplatin; FOLFOX, Oxaliplatin + 5-Fu; Paclitaxel-based agents, Paclitaxel + Oxaliplatin, Paclitaxel + Cisplatin, Paclitaxel + 5-Fu; ECOG, Eastern Cooperative Oncology Group.